Treating patients who have stage III non-small cell lung cancer (NSCLC) with durvalumab concurrent with chemoradiotherapy (CRT) and continuing as consolidation therapy did not improve overall survival ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback